The GGGGCC Repeat Expansion in C9ORF72 in a Case with Discordant Clinical and FDG-PET Findings: PET Trumps Syndrome

A hexanucleotide repeat expansion in the chromosome 9 open reading frame 72 (C9ORF72) gene was recently discovered as the cause underlying frontotemporal degeneration (FTD) and/or amyotrophic lateral sclerosis (ALS) linked to chromosome 9 (c9FTD/ALS). In this atypical case of c9FTD/ALS, the proband presented with amnestic mild cognitive impairment which evolved into Alzheimer’s disease (AD)-type dementia and later developed ALS. Fluorodeoxyglucose-positron emission tomography of the brain demonstrated mild hypometabolism involving the medial frontal and lateral temporal lobes, left more so than right, which progressed over time. He was subsequently confirmed to have the C9ORF72 expansion. This report highlights the need to consider mutations in the FTD-associated genes when a familial disorder is suggested and neuroimaging studies reveal findings atypical of an AD pathophysiological process despite the typical anterograde amnestic syndrome.

[1]  D. Neary,et al.  Analysis of the hexanucleotide repeat in C9ORF72 in Alzheimer's disease , 2012, Neurobiology of Aging.

[2]  D. Geschwind,et al.  Atypical, slowly progressive behavioural variant frontotemporal dementia associated with C9ORF72 hexanucleotide expansion , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[3]  D. Neary,et al.  Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. , 2012, Brain : a journal of neurology.

[4]  Y. Pijnenburg,et al.  The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions. , 2012, Brain : a journal of neurology.

[5]  H. Feldman,et al.  Clinical and pathological features of familial frontotemporal dementia caused by C9ORF72 mutation on chromosome 9p. , 2012, Brain : a journal of neurology.

[6]  David T. Jones,et al.  Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72 , 2012, Brain : a journal of neurology.

[7]  C. Jack,et al.  Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics , 2012, Brain : a journal of neurology.

[8]  Nick C Fox,et al.  Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features , 2012, Alzheimer's & Dementia.

[9]  A. Singleton,et al.  Repeat expansion in C9ORF72 in Alzheimer's disease. , 2012, The New England journal of medicine.

[10]  T. Ferman,et al.  Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72 , 2011, Acta Neuropathologica.

[11]  B. Boeve,et al.  Neuropsychological assessment of patients with dementing illness , 2011, Nature Reviews Neurology.

[12]  David Heckerman,et al.  A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD , 2011, Neuron.

[13]  Bruce L. Miller,et al.  Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS , 2011, Neuron.

[14]  Nick C Fox,et al.  Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. , 2011, Brain : a journal of neurology.

[15]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[16]  F. Panza,et al.  The APOE gene locus in frontotemporal dementia and primary progressive aphasia. , 2011, Archives of neurology.

[17]  B. Miller,et al.  Classification of primary progressive aphasia and its variants , 2011, Neurology.

[18]  R. Petersen,et al.  Robust and expanded norms for the Dementia Rating Scale. , 2010, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.

[19]  R. Petersen,et al.  Alzheimer disease-like phenotype associated with the c.154delA mutation in progranulin. , 2010, Archives of neurology.

[20]  C. Jack,et al.  Comparison of 18F-FDG and PiB PET in Cognitive Impairment , 2009, Journal of Nuclear Medicine.

[21]  Massimo Filippi,et al.  Apolipoprotein E ε4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia , 2009, Proceedings of the National Academy of Sciences.

[22]  K. Josephs.  Frontotemporal dementia and related disorders: Deciphering the enigma , 2008, Annals of neurology.

[23]  G. Waldemar,et al.  Alzheimer disease‐like clinical phenotype in a family with FTDP‐17 caused by a MAPT R406W mutation , 2008, European journal of neurology.

[24]  C. DeCarli,et al.  FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. , 2007, Brain : a journal of neurology.

[25]  D. Geschwind,et al.  Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C→T (Arg493X) mutation: an international initiative , 2007, The Lancet Neurology.

[26]  E. Tangalos,et al.  Mayo's Older Americans Normative Studies: Visual Form Discrimination and copy trial of the Rey–Osterrieth Complex Figure , 2007, Journal of clinical and experimental neuropsychology.

[27]  H. Akiyama,et al.  TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. , 2006, Biochemical and biophysical research communications.

[28]  Bruce L. Miller,et al.  Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis , 2006, Science.

[29]  E. Tangalos,et al.  Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. , 2006, Archives of neurology.

[30]  H. Horvitz,et al.  A locus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia , 2006, Neurology.

[31]  A. Goate,et al.  Tau (MAPT) mutation Arg406Trp presenting clinically with Alzheimer disease does not share a common founder in Western Europe , 2003, Human mutation.

[32]  J. Morris,et al.  Current concepts in mild cognitive impairment. , 2001, Archives of neurology.

[33]  B Miller,et al.  Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. , 2001, Archives of neurology.

[34]  J. Haines,et al.  Linkage of familial amyotrophic lateral sclerosis with frontotemporal dementia to chromosome 9q21-q22. , 2000, JAMA.

[35]  M. Swash,et al.  El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[36]  R. Faber,et al.  Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. , 1999, Neurology.

[37]  E. Tangalos,et al.  Mayo's older Americans normative studies: category fluency norms. , 1998, Journal of clinical and experimental neuropsychology.

[38]  D. Schaid,et al.  Apolipoprotein E: risk factor for Alzheimer disease. , 1994, American journal of human genetics.

[39]  K P Offord,et al.  A short test of mental status: description and preliminary results. , 1987, Mayo Clinic proceedings.

[40]  E. Tangalos,et al.  Neuropsychological tests' norms above age 55: COWAT, BNT, MAE token, WRAT-R reading, AMNART, STROOP, TMT, and JLO , 1996 .

[41]  E. Tangalos,et al.  Mayo's older americans normative studies: WAIS-R norms for ages 56 to 97 , 1992 .

[42]  James F. Malec,et al.  Mayo's older americans normative studies: Updated AVLT norms for ages 56 to 97 , 1992 .